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Galcanezumab in episodic migraine:
subgroup analyses of efficacy by high
versus low frequency of migraine
headaches in phase 3 studies
(EVOLVE-1 & EVOLVE-2)
Stephen D. Silberstein1*, Virginia L. Stauffer2, Katie A. Day2, Sarah Lipsius3 and Maria-Carmen Wilson4
Abstract
Background: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those
with low-frequency episodic migraine (LFEM). Acute treatment overuse increases the risk of migraine chronification
in patients with HFEM. Galcanezumab, a humanized monoclonal antibody binding calcitonin gene-related peptide
(CGRP), is effective for migraine prevention with a favorable safety profile. Here, we investigate whether there are
differences in galcanezumab efficacy in patients with LFEM or with HFEM.
Methods: Data were pooled from two double-blind, placebo-controlled phase 3 trials; EVOLVE-1 and EVOLVE-2.
Patients were 18–65 years old, experienced 4–14 monthly migraine headache days (MHDs) for ≥1 year prior, with
onset at < 50 years of age. Migraine headaches were tracked via electronic patient-reported outcome system and
randomization was stratified by low (LFEM; 4–7 monthly MHDs) or high (HFEM; 8–14 monthly MHDs) frequency.
Subgroup analysis compared the HFEM and LFEM subgroups with a linear or generalized linear mixed model
repeated measures approach.
Results: The intent-to-treat patients (N = 1773) had a mean age of 41.3 years, were mostly white (75%), female (85%), and
66% of patients had HFEM. In both the LFEM and HFEM subgroups, the overall (Months 1–6) and monthly changes from
baseline in monthly MHDs and monthly MHDs with acute medication use compared with placebo were statistically
significantly reduced for galcanezumab 120-mg and 240-mg. Galcanezumab (120-mg and 240-mg) significantly
decreased the overall and monthly MHDs with nausea and/or vomiting, and with photophobia and phonophobia versus
placebo in patients with LFEM or HFEM. In both subgroups, the mean overall (Months 1–6) and monthly percentages of
patients with ≥50%, ≥75%, and 100% reduction in monthly MHDs from baseline were statistically significantly greater in
patients receiving either dose of galcanezumab versus placebo. Galcanezumab (120-mg and 240-mg) significantly
improved the Migraine-Specific Quality of Life Questionnaire role function-restrictive domain score as well as the Migraine
Disability Assessment total score versus placebo for patients with LFEM or HFEM. There were no significant subgroup-by-
treatment interactions.
Conclusions: Galcanezumab was as effective in patients with HFEM as in those with LFEM. Associated symptoms, quality
of life, and disability were similarly improved in patients with HFEM or LFEM.
Trial registration: NCT02614183, NCT02614196.
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Background
Migraine is the second global cause of years lived with
disability (YLDs), representing 45.1 million (95% uncer-
tainty interval [95%UI]: 29.0–62.8 million) YLDs [1]. Its
global age-standardized prevalence of 18.9% (95%UI:
18.1–19.7%) for women and 9.8% (95%UI: 9.4–10.2%)
for men represents a world-wide total of 1.04 billion
(95%UI: 1.00–1.09 billion) individuals with migraine [2].
Despite this, it is often under-treated and inadequately
recognized [1–3].
Migraine frequency varies. While episodic migraine
(EM) is not specifically defined in the 3rd edition of the
International Classification of Headache Disorders
(ICHD) [4], it refers to a headache frequency of less than
15 headache days per month in patients who have mi-
graine [3]. The ICHD-3 defines chronic migraine (CM)
as 15 or more headache days per month with at least 8
days meeting ICHD criteria for migraine with or without
aura [4]. Although using 15 days per month as a divide
between EM and CM appears arbitrary, there are mean-
ingful differences in epidemiology, as CM may be more
difficult to treat, associated with more comorbidities,
with more severe and longer-lasting migraine headaches,
and greater functional impact than EM [3]. Approxi-
mately 2% to 3% of patients with EM progress to CM
annually [3, 5], and in one study, 26% of patients with
CM reverted to EM over 2 years [5]. This suggests there
may be some overlap in biology between CM and EM
experienced at higher frequencies; consequently, there
may be differences in the responses of patients with
high-frequency EM (HFEM) compared to those with
low-frequency EM (LFEM).
Unlike CM, there is no standardized definition of
LFEM and HFEM, and different studies have used fre-
quencies from 8 to 14 and 10 to 14 migraine headache
days (MHDs) per month to define HFEM [6–8]. The re-
cent approvals of monoclonal antibodies to calcitonin
gene-related peptide (CGRP), fremanezumab and galca-
nezumab, along with approval of monoclonal antibodies
to the CGRP receptor, erenumab, for migraine preven-
tion open a new chapter in the management of EM and
CM. The present investigation was undertaken to com-
pare the effect of galcanezumab to placebo in patients
with LFEM and HFEM to assess if the treatment effect
of galcanezumab differed in these 2 subgroups of pa-
tients categorized by migraine headache frequency.
Methods
Study design
Patient data were pooled from 2 phase 3 multicenter,
placebo-controlled, randomized clinical trials, EVOLVE-
1 (NCT02614183) and EVOLVE-2 (NCT02614196), de-
signed to examine the ability of galcanezumab to reduce
the monthly number of MHDs in patients with episodic
migraine. EVOLVE-1 was conducted at 90 study sites in
the United States and Canada, and EVOLVE-2 was con-
ducted at 109 study sites in the United States, United
Kingdom, Netherlands, Spain, Czech Republic, Germany,
Argentina, Israel, Korea, Taiwan, and Mexico. The details
of the clinical trials have been published [9, 10]. The study
protocols were reviewed and approved by the appropriate
institutional review board for each of the study sites. All
patients gave written informed consent to participate in
the study. The studies were conducted with the approval
of the independent Ethics Committees of the participating
institutes and in accordance with the Declaration of
Helsinki, the International Conference on Harmonization
Good Clinical Practice guidelines, and local regulations.
Both trials consisted of 2 study periods prior to the
randomization step. Study period 1 (3 to 45 days) con-
sisted of a comprehensive medical examination and
wash-out of migraine preventive medications. Study
period 2 (30–40 days) was the prospective baseline
period, when patients logged in daily to the electronic
patient-reported outcomes (ePRO) system and reported
on the occurrence of headaches, headache duration,
headache features, severity of headache, and use of head-
ache medication in order to confirm migraine headache
frequency. Study period 3 (6 months) was the double-
blind treatment phase, where patients were randomized
(2:1:1) to receive subcutaneous injections of either pla-
cebo, 120-mg galcanezumab, or 240-mg of galcanezu-
mab during monthly office visits. Patients in the 120-mg
galcanezumab group received an initial loading dose of
240-mg. Patients in all groups received 2 injections at
each dosing visit in order to preserve blinding through-
out the study. Patients continued daily-diary entries and
were permitted to take acute migraine medications as
needed. Medications containing opioids or barbiturates
were limited to three days monthly and other migraine
preventive treatments were excluded. Randomization
was stratified by country and migraine frequency (< 8 vs
≥8 MHDs/month) at baseline in order to achieve bal-
ance among groups.
Patients enrolled in the study were between the ages
of 18 and 65 years and had a diagnosis of migraine with
or without aura [11] for ≥1 year prior to enrollment and
onset prior to the age of 50 years. In order to be in-
cluded in the study, patients also had to have 4 to 14
MHDs per month and at least 2 migraine episodes dur-
ing the prospective baseline period, as well as 80% com-
pliance in using the electronic diary.
Patients were excluded if they participated in a clinical
trial within the previous 30 days, were previously exposed
to a CGRP antibody, including galcanezumab, or had
known hypersensitivity to multiple drugs, monoclonal
antibodies or other therapeutic proteins. Patients with a
history of persistent daily headache, cluster headache, or
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migraine subtypes (hemiplegic, ophthalmoplegic, or mi-
graine with brainstem aura, or chronic migraine) as de-
fined by ICHD-3 β [11], as well as those previously failing
to respond to ≥3 migraine preventive treatments from dif-
ferent therapeutic classes, or presence of a medical condi-
tion that would preclude study participation including but
not limited to pregnancy, suicidal ideation within the past
month, history of substance abuse or dependence in the
past year, recent history of acute cardiovascular events,
and/or serious cardiovascular risk based on history or
electrocardiogram findings were excluded. Patients who
used opioids or barbiturate-containing analgesics more
than twice per month in more than 2 of the past 6months
were also excluded, as were those who were pregnant.
Assessments used
Efficacy analyses were performed on the intent-to-treat
(ITT) population, which included randomized patients
who received at least one dose of galcanezumab or pla-
cebo. Assessments were based on the responses made by
the patients in the ePRO daily diary. An automated algo-
rithm was used to define each day as either a migraine
day, probable migraine day (headache with or without
aura lasting ≥30min), non-migraine headache day, or no
headache day. A MHD was defined as a calendar day on
which a migraine headache or probable migraine head-
ache occurred. The number of monthly MHDs and
number of monthly MHDs with acute medication use,
with aura, with nausea and/or vomiting, with photopho-
bia and phonophobia, and with prodrome for Months 1
to 6 were determined from the ePRO data. In addition,
the Migraine-Specific Quality of Life Questionnaire v2.1
Role Function-Restrictive (MSQ-RFR v2.1) assessments
were performed during the monthly visits at each study
site. The Migraine Disability Assessment (MIDAS) was
performed at Months 3 and 6.
Statistical analysis
The frequency of episodic migraine headaches was de-
termined for each patient during the prospective base-
line. Patients were then categorized post-hoc into LFEM
(4–7 MHD) or HFEM (8–14 MHD) monthly migraine
frequency subgroups. The baseline symptoms, function-
ing, and disability for the 2 migraine frequency sub-
groups were compared using an Analysis of Variance
model with terms for study and baseline migraine fre-
quency group in order to determine if illness burden
was impacted by monthly migraine frequency. Analyses
within subgroups were conducted for continuous effi-
cacy measures using a mixed models repeated measures
approach with terms for treatment, pooled country
(study), month, and treatment-by-month interaction,
baseline value, and baseline-by-month interaction. The
model used to compare subgroups had additional terms for
subgroup, subgroup-by-treatment, subgroup-by-month,
and subgroup-by treatment-by-month interaction. The pri-
mary endpoint of overall mean change in monthly MHDs
was the average of values obtained at Months 1 to 6 of the
6-month double-blind treatment phase.
Change from baseline of continuous variables (i.e., MHD,
MHD with acute medication use, MHD with nausea and/
or vomiting, MHD with photophobia and phonophobia,
MSQ-RFR and Patient Global Impression of Severity [PGI-
S]) were analyzed by month and overall (for Months 1 to
6); MSQ-RFR and PGI-S were also analyzed overall (for
Months 4 to 6). The efficacy measures of ≥50%, ≥75%, and
100% reduction from baseline (“response”) in the number
of monthly MHDs were analyzed within each subgroup by
month and overall (Months 1 to 6) using a categorical,
pseudo-likelihood-based repeated measures model for
binary outcomes with terms for treatment, study, month,
treatment*month, and baseline MHD. Subgroups were
compared using this model with additional terms for sub-
group, subgroup-by-treatment, subgroup-by-month, and
subgroup-by-treatment-by-month interaction.. Treatment
effects were evaluated based upon a two-sided, 0.05 signifi-
cance level. Effects for continuous (binary) outcomes are
presented using model estimated means (proportions)
while differences in continuous outcomes between groups
were shown using mean differences along with 95% confi-
dence intervals. The subgroup-by-treatment interaction
was tested at a two-sided, 0.1 significance level. All statis-
tical analyses were performed with the use of SAS software
version 9.4 (SAS Institute, Cary, NC).
Results
Patient disposition and baseline characteristics
A total of 1773 patients were included in the ITT popu-
lation, with 597 (34%) in the LFEM group and 1176
(66%) in the HFEM group. Overall, the patient popula-
tion was largely female (84.6%), white (75.2%), and
North American (73.6%), and had a mean time since mi-
graine diagnosis of 20.3 years. The mean (standard devi-
ation [SD]) age of the patients was 41.3 (11.4) years, and
there was no significant difference in age between the
LFEM and HFEM groups. At baseline, patients with
HFEM had significantly more MHDs, and MHDs with
acute medication use, with nausea and/or vomiting, with
photophobia and phonophobia, with aura, and with pro-
dromal symptoms than did patients with LFEM. Patient
baseline characteristics are summarized in Table 1.
Change in monthly MHDs
Galcanezumab 120-mg and 240-mg significantly reduced
the mean number of monthly MHDs over the 6-month
treatment period in patients with LFEM and in those
with HFEM compared to placebo (Table 2). These re-
ductions represent changes of − 1.8 (95% confidence
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intervals [CI]: − 2.35, − 1.32) and − 1.4 (95% CI: − 1.88,
− 0.84) in monthly MHDs relative to placebo for 120-mg
and 240-mg of galcanezumab, respectively, for patients
with LFEM and − 2.0 (95% CI: − 2.56, − 1.52) and − 2.1
(95% CI: − 2.58, − 1.54) in monthly MHDs relative to
placebo for 120-mg and 240-mg of galcanezumab, re-
spectively, for patients with HFEM. It is noteworthy that
the differences relative to placebo are similar, regardless
of migraine frequency, and reflect the higher placebo re-
sponse seen in patients with HFEM. Both doses of galca-
nezumab significantly reduced the numbers of MHDs at
each month over the 6-month treatment period relative
to reductions in the placebo groups of patients with
LFEM and HFEM (Fig. 1). The treatment-by-subgroup
interaction was not statistically significant indicating that
the treatment effect did not differ across the LFEM and
HFEM subgroups.
Change in monthly MHDs with acute medication use
Galcanezumab 120-mg and 240-mg significantly reduced
the mean number of monthly MHDs with acute medica-
tion use over the 6-month treatment period in patients
with LFEM or HFEM compared to placebo (Table 2).
For the patients with LFEM, these changes represent re-
ductions of 1.7 (95% CI: − 2.11, − 1.20) and 1.4 (95% CI:
− 1.82, − 0.89) in MHDs beyond those due to placebo,
and reductions of 1.9 (95% CI: − 2.35, − 1.45) and 1.9
(95% CI: − 2.35, − 1.43) MHDs relative to placebo for
Table 1 Baseline characteristics
LFEM Mean (SD) HFEM Mean (SD) LFEM vs HFEM p-value *
Number of patients (%) 597 (33.7) 1176 (66.3)
Age at randomization, years 42 (11.4) 41 (11.4) .069
MHDs 5.79 (1.11) 10.82 (2.01) <.001
MHDs with acute medication use 4.82 (1.73) 8.81 (3.27) <.001
MHDs with nausea and vomiting 2.20 (1.98) 4.66 (3.36) <.001
MHDs with photophobia and phonophobia 4.08 (2.17) 8.26 (3.52) <.001
MHDs with aura 1.40 (2.03) 3.04 (3.65) <.001
MHDs with prodrome 1.89 (2.11) 3.86 (3.77) <.001
MSQ-RFR score 55.8 (15.8) 49.5 (15.4) <.001
MIDAS total score 26.3 (22.9) 36.6 (30.7) <.001
* P-value from Analysis of Variance model with terms for study, baseline MHD frequency subgroup
HFEM: high-frequency episodic migraine; ITT: intent-to-treat; LFEM: low-frequency episodic migraine; MHDs: migraine headache days; MIDAS: Migraine Disability
Assessment; MSQ-RFR v2.1: Migraine-Specific Quality of Life Questionnaire v2.1 Role Function-Restrictive
Table 2 Reduction over Months 1 to 6 in mean monthly MHDs with associated symptoms
LFEM Average of Months 1–6 (95% CI) HFEMAverage of Months 1–6 (95% CI)
Monthly MHDs with: Placebo (N = 295) GMB 120 mg (N = 150) GMB 240 mg (N = 145) Placebo (N = 580) GMB 120 mg (N = 286) GMB 240 mg (N = 283)
All MHDs −0.9 (−1.4,-0.5) −2.8 (−3.3, − 2.2) −2.3 (− 2.8, − 1.7) −3.4 (− 3.8, 3.0) −5.4 (− 5.9, − 4.9) −5.5 (−6.0, − 4.9)
p vs placebo <.001 <.001 <.001 <.001
Acute medication
use
− 0.8 (− 1.2, − 0.4) − 2.4 (− 2.9, − 2.0) −2.1 (− 2.6, − 1.7) −2.7 (− 3.1, − 2.7) −4.6 (− 5.1, − 4.2) −4.6 (− 5.0, − 4.2)
p vs placebo <.001 <.001 <.001 <.001
Prodromal
symptoms
−0.6 (− 0.9, − 0.4) −1.1 (− 1.4, − 0.7) −1.1 (− 1.4, − 0.7) −1.4 (− 1.6, − 1.1) − 2.2 (− 2.6, − 1.9) −2.0 (− 2.4, − 1.7)
p vs placebo .006 .006 <.001 <.001
Aura −0.4 (− 0.6, − 0.2) −0.8 (− 1.0, − 0.5) −0.7 (− 0.9, − 0.4) − 1.3 (− 1.5, − 1.0) −1.8 (− 2.0, − 1.5) −1.8 (− 2.1, − 1.5)
p vs placebo .005 .055 <.001 <.001
Photophobia and
phonophobia
−0.5 (− 0.9, − 0.1) −1.9 (− 2.4, − 1.4) −1.7 (− 2.2, − 1.2) − 2.5 (− 2.9, − 2.1) − 4.2 (− 4.7, − 3.7) −4.1 (− 4.6, − 3.6)
p vs placebo <.001 <.001 <.001 <.001
Nausea and/or
vomiting
−0.2 (− 0.5, 0.1) −0.9 (− 1.2, − 0.6) −0.9 (− 1.2, − 0.6) −1.5 (− 1.8, − 1.2) −2.6 (− 2.9, − 2.2) −2.4 (− 2.8, − 2.1)
p vs placebo <.001 <.001 <.001 <.001
Abbreviations: 95% CI: 95% Confidence interval; GMB: galcanezumab; HFEM: high-frequency episodic migraine; LFEM: low-frequency episodic
migraine; MHD: migraine headache day
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both doses in patients with HFEM. Both doses of gal-
canezumab showed significant reductions relative to
placebo in numbers of MHDs with acute medication
use at each month over the 6-month treatment period
in patients with LFEM and HFEM (Table 2). The
treatment effect was consistent across the LFEM and
HFEM subgroups as evidenced by the non-significant
treatment-by-subgroup interaction.
Change in monthly MHDs with symptoms associated
with migraine
Galcanezumab 120-mg and 240-mg significantly reduced
the mean numbers of monthly MHDs with aura, prodrome
symptoms, nausea and/or vomiting, and with photophobia
and phonophobia over the 6-month treatment period in pa-
tients with LFEM and with HFEM compared to placebo
(Table 2). For the patients with LFEM, these changes
ranged from − 0.7 (95% CI: − 0.9, − 0.4) MHDs, for days
with aura, to − 1.9 (95% CI: − 2.4, − 1.4) days with photo-
phobia and phonophobia. Likewise for patients with HFEM,
the change in MHDs with associated symptoms ranged
from − 1.8 (95% CI: − 2.0, − 1.5) MHDs with aura to − 4.2
(95% CI: − 4.7, − 3.7) MHDs with photophobia and phono-
phobia (Table 2). The treatment-by-subgroup interaction
was not statistically significant indicating consistency of the
treatment effect across the subgroups.
Response rates in patients with LFEM and HFEM
Both doses of galcanezumab produced similar ≥50% re-
sponse rates overall (for Months 1–6), that were statisti-
cally significantly greater than placebo, in patients with
LFEM or HFEM (Fig. 2). The overall estimated ≥50% re-
sponse rate (standard error [SE]) over the 6-month treat-
ment period was 63% (3%) and 55% (3%) for patients
with LFEM who were treated with 120-mg and 240-mg
of galcanezumab, respectively (Fig. 2). The average re-
sponse rates over the same period for patients with
HFEM treated with 120-mg and 240-mg of galcanezu-
mab, respectively, were 60% (2%) and 61% (2%). The
percentage of patients with ≥50% response rates was sig-
nificantly greater than placebo at each month for both
doses of galcanezumab in both the LFEM and HFEM
groups (Fig. 2). Likewise, both doses of galcanezumab re-
sulted in ≥75% (Fig. 3) and 100% (Fig. 4) response rates
that were significantly greater than those of placebo in
both the LFEM and HFEM groups. As with the 50% re-
sponse rate, the proportion of patients with a ≥ 75% re-
sponse did not differ between the LFEM and HFEM
groups. Likewise, the mean over Months 1 to 6 of the
percentage of patients with a 100% response rate was
also similar between the 2 EM frequency subgroups.
The percentage of patients with a ≥ 75% response rate
(Fig. 3) and a 100% response rate (Fig. 4) at each month
who received galcanezumab was significantly greater
Fig. 1 The overall least-squares (LS) mean change from baseline in monthly MHDs is shown for patients with LFEM and HFEM receiving placebo,
120-mg, or 240-mg of galcanezumab in the upper row. The monthly LS mean changes in monthly MHDs for patients receiving these treatments
is shown in the bottom row for patients with LFEM and with HFEM. ***p≤ .001, **p≤ .01, *p≤ .05 vs placebo
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Fig. 2 The overall mean percentage of patients with ≥50% reduction from baseline in monthly MHDs across Months 1–6 is shown for patients
with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly percentage of patients with ≥50%
reduction in MHDs is shown in the bottom row for patients with LFEM and with HFEM. ***p≤ .001, **p≤ .01, *p ≤ .05 vs placebo
Fig. 3 The overall mean percentage of patients with ≥75% reduction from baseline in monthly MHDs across Months1–6 is shown for patients
with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly percentage of patients with ≥75%
reduction in MHDs is shown in the bottom row for patients with LFEM and with HFEM. ***p≤ .001, **p≤ .01, *p ≤ .05 vs placebo
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than the percentage achieving these response rates with
placebo within each of the EM frequency subgroups.
There was a statistically significant pairwise subgroup-by-
treatment interaction (p = .09) for the ≥50% response rate
between galcanezumab 120-mg and placebo for the over-
all (Months 1–6) time period. However, this interaction
was deemed spurious and not meaningful as neither the
subgroup-by-treatment interaction for galcanezumab 240-
mg versus placebo nor the overall interaction were statisti-
cally significant.
Waterfall plots showing results for the primary end-
point by number of migraine days at baseline are pre-
sented in Fig. 5 by individual study (EVOLVE-1 and
EVOLVE-2). These plots provide the percentage change
from baseline in MHDs for each patient by baseline
number of MHDs, and are color-coded for ranges of
baseline MHDs. For galcanezumab-treated patients,
there was no discernible difference in pattern between
patients with the most and least MHDs at baseline.
Disability and quality of life
Galcanezumab 120-mg and 240-mg produced similar in-
creases in MSQ-RFR scores overall at Months 4 to 6 in
patients with both LFEM and with HFEM (Fig. 6). For
both the LFEM and HFEM groups, with both doses of gal-
canezumab, the increases in MSQ-RFR scores were sig-
nificantly greater than those of the placebo group at all
visits throughout the 6-month treatment period (Fig. 6).
Likewise, mean reductions in the MIDAS total scores
overall (average of Months 3 and 6), and at Months 3 and
6, were significantly greater than those in the placebo
group for both doses of galcanezumab for patients with
LFEM or with HFEM (Fig. 7). Treatment-by-subgroup in-
teractions were not statistically significant for MSQ-RFR
and MIDAS total score confirming consistency of treat-
ment effect across the LFEM and HFEM subgroups.
Discussion
Galcanezumab given in monthly doses of 120-mg and
240-mg was effective in reducing the numbers of MHDs
in patients with LFEM and with HFEM. Moreover, as
the waterfall plots showed, galcanezumab was effective
regardless of the baseline frequency of MHDs. Change
relative to the patient’s baseline is a useful measure of
comparison across baseline groupings since a reduction
of, for example, 5 MHDs could represent 100% response
for a patient with 5 MHDs at baseline but less than 50%
response for one with 14 MHDs at baseline. The plots of
percentage change in the galcanezumab treatment
groups show that for every grouping by baseline number
of MHDs, there was a similar set of results, with a few
patients in most groups showing worsening from base-
line, but a substantial number of patients in each group
showing clinically significant improvement from baseline
(> 50% reduction in MHDs relative to baseline) for the
episodic migraine studies. In addition, galcanezumab re-
duced the monthly MHDs with acute medication use,
Fig. 4 The overall mean percentage of patients with 100% reduction in monthly MHDs across Months 1–6 is shown for patients with LFEM and
HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly percentage of patients with 100% reduction in
MHDs is shown in the bottom row for patients with LFEM and with HFEM. ***p ≤ .001, **p ≤ .01, *p≤ .05 vs placebo
Silberstein et al. The Journal of Headache and Pain           (2019) 20:75 Page 7 of 11
with prodromal symptoms other than aura, with aura,
with nausea and/or vomiting, and with photophobia and
phonophobia, by similar degrees in patients with LFEM
and with HFEM. Migraine had a significantly greater im-
pact on the quality of life and disability of patients with
HFEM than those with LFEM, as indicated by the sig-
nificant differences in MSQ-RFR and MIDAS scores at
baseline. Both doses of galcanezumab produced similar
levels of improvement in both the MSQ-RFR and
MIDAS total scores in patients with LFEM and with
HFEM. These results suggest that galcanezumab is
equally effective in patients with episodic migraine, re-
gardless of headache frequency.
In addition to migraine headache frequency, migraine
severity, migraine duration, level of disability and symp-
toms, the impact on patient, and response to acute treat-
ment are important factors for the initiation of
preventive treatment [12]. The advisory group for the
American Migraine Prevalence and Prevention study
recommended that preventive therapy be offered to mi-
graine patients reporting either ≥6 MHDs per month, ≥4
MHDs per month with some impairment, or ≥ 3 MHDs
Fig. 5 Waterfall plots showing the percent change from baseline in number of MHDs of Month 1 to 6 by baseline number of migraine headache days
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Fig. 6 The overall least-squares (LS) mean change in the Migraine-Specific Quality of Life Questionnaire role function-restrictive domain (MSQ-
RFR) is shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The monthly LS mean
changes in MSQ-RFR for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM. ***p ≤ .001,
**p≤ .01, *p ≤ .05 vs placebo
Fig. 7 The overall least-squares (LS) mean change in Migraine Disability Assessment (MIDAS) total Score for the average of Months 3 and 6 is
shown for patients with LFEM and HFEM receiving placebo, 120-mg, or 240-mg of galcanezumab in the upper row. The LS mean changes in
MIDAS total score at Months 3 and 6 for patients receiving these treatments is shown in the bottom row for patients with LFEM and with HFEM.
***p≤ .001, **p ≤ .01, *p≤ .05 vs placebo
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per month with severe impairment or requiring bed rest
[13]. Until the recent development of the monoclonal
antibodies to CGRP or the CGRP receptor, migraine pre-
ventive therapies have not been migraine-specific, and
have often had adverse events and poor patient compli-
ance [3, 14, 15].
The recently approved monoclonal antibodies to
CGRP or its receptor, fremanezumab, galcanezumab,
and erenumab, as well as eptinezumab which is still in
development, have been reported as effective in episodic
migraine, are well tolerated, and have few adverse events
[9, 10, 16–20]. The most commonly reported adverse
events associated with galcanezumab in the EVOLVE-1
and EVOLVE-2 studies were injection site pain and asso-
ciated injection site reactions [9,10,]. Moreover, in a re-
cent phase 3 randomized clinical trial, galcanezumab
was effective in patients with chronic migraine, and the
most common adverse events were related to injection
site adverse events [21].
A potential limitation of the present study is that for
both EVOLVE-1 and EVOLVE-2, the definition of a
MHD included the presence of migraine headache and
probable migraine headache [9, 10]. This definition may
make direct comparisons to literature guidelines based
solely on migraine headache days, exclusive of probable
migraine, somewhat difficult.
Conclusions
In summary, once-monthly galcanezumab reduces the
frequency of migraine headache days in patients with
LFEM or HFEM. The numbers of days with acute medi-
cation use are also reduced, which helps lower the risk
of developing medication-overuse headache. Reduction
in MHDs with associated symptoms of nausea and
vomiting, or photophobia and phonophobia, along with
the changes in MSQ-RFR and MIDAS scores, suggest
that galcanezumab treatment reduces the disability
caused by migraine and increases quality of life in pa-
tients with either LFEM or HFEM.
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